ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD. Financials Zylox-Tonbridge Medical Technology Co., Ltd.
Equities
2190
CNE100004JD2
Medical Equipment, Supplies & Distribution
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.3 HKD | -1.72% |
|
+1.98% | -17.20% |
| 03-22 | Zylox-Tonbridge Shrinks Loss by 31% in Fiscal 2023 | MT |
| 03-21 | Zylox-Tonbridge Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 6,907 | 3,769 | 3,174 | 3,174 | - |
| Enterprise Value (EV) 1 | 3,987 | 2,578 | 3,704 | 2,180 | 2,164 |
| P/E ratio | - | -33.4 x | -47.1 x | 44.1 x | 19.9 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 38.8 x | 11.3 x | 7.02 x | 4.16 x | 2.92 x |
| EV / Revenue | 22.4 x | 7.72 x | 7.02 x | 2.86 x | 1.99 x |
| EV / EBITDA | -19.4 x | -13 x | -44.9 x | 28.7 x | 13.8 x |
| EV / FCF | - | -11.4 x | -8.25 x | -14.9 x | -33.8 x |
| FCF Yield | - | -8.77% | -12.1% | -6.7% | -2.96% |
| Price to Book | 1.95 x | 1.21 x | 1.04 x | 1.04 x | 0.98 x |
| Nbr of stocks (in thousands) | 332,401 | 332,401 | 327,458 | 327,458 | - |
| Reference price 2 | 20.78 | 11.34 | 9.694 | 9.694 | 9.694 |
| Announcement Date | 15/03/22 | 29/03/23 | 21/03/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | 27.63 | 177.9 | 334.1 | 527.8 | 763.6 | 1,087 |
| EBITDA 1 | - | -205.9 | -198 | -47.4 | 76 | 157.2 |
| EBIT 1 | - | -212.5 | -208.4 | -156.5 | 51 | 160.5 |
| Operating Margin | - | -119.43% | -62.38% | -29.66% | 6.68% | 14.76% |
| Earnings before Tax (EBT) 1 | - | - | -113.6 | -78.73 | 76.33 | 171.3 |
| Net income 1 | - | - | -113.6 | -78.73 | 72 | 161.3 |
| Net margin | - | - | -33.99% | -14.92% | 9.43% | 14.84% |
| EPS 2 | -0.5200 | - | -0.3400 | -0.2400 | 0.2200 | 0.4867 |
| Free Cash Flow 1 | - | - | -226.1 | -258 | -146 | -64 |
| FCF margin | - | - | -67.66% | -51.16% | -19.12% | -5.89% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 22/06/21 | 15/03/22 | 29/03/23 | 21/03/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 2,919 | 1,191 | 1,046 | 994 | 1,011 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -226 | -258 | -146 | -64 |
| ROE (net income / shareholders' equity) | - | -11.2% | -3.64% | 0.09% | 2.33% | 4.72% |
| ROA (Net income/ Total Assets) | - | - | -3.49% | -0.57% | 2.1% | 4.37% |
| Assets 1 | - | - | 3,251 | 3,294 | 3,429 | 3,695 |
| Book Value Per Share 2 | - | 10.70 | 9.370 | 9.320 | 9.340 | 9.870 |
| Cash Flow per Share 2 | - | - | -0.2800 | 0.0500 | 0.1200 | 0.3300 |
| Capex 1 | - | - | 135 | 118 | 98.3 | 99.7 |
| Capex / Sales | - | - | 40.33% | 23.33% | 12.88% | 9.17% |
| Announcement Date | 22/06/21 | 15/03/22 | 29/03/23 | 21/03/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
9.694
CNY
Average target price
14.11
CNY
Spread / Average Target
+45.53%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.20% | 438M | |
| +13.16% | 129B | |
| -8.76% | 10.77B | |
| +3.60% | 9.05B | |
| +19.75% | 7.38B | |
| +22.28% | 4.88B | |
| +7.55% | 3.41B | |
| -0.21% | 3.07B | |
| -4.80% | 2.24B | |
| -4.72% | 2.12B |
- Stock Market
- Equities
- 2190 Stock
- Financials Zylox-Tonbridge Medical Technology Co., Ltd.
